Literature DB >> 15475993

The prevention of early-onset neonatal group B streptococcus infection: technical report from the New Zealand GBS Consensus Working Party.

Norma Campbell1, Alison Eddy, Brian Darlow, Peter Stone, Keith Grimwood.   

Abstract

AIMS: Early-onset neonatal group B streptococcus (GBS) is the leading infectious cause of disease in newborn babies. Since intrapartum antibiotics interrupt vertical GBS transmission, this is now a largely preventable public health problem. An important first step is to develop (then implement) nationally, agreed prevention policies.
METHODS: Representatives from the New Zealand College of Midwives, the Paediatric Society of New Zealand, the New Zealand Committee of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, the Royal New Zealand College of General Practitioners, and the Homebirth Association met to review evidence that will assist in the formulation of GBS prevention policies that are most suitable for New Zealand.
RESULTS: The Technical Working Group noted that (i) no strategy will prevent all cases of early-onset GBS infection, (ii) intrapartum antibiotics are associated with rare, but serious, adverse effects, (iii) concerns remain over developing antibiotic resistance, (iv) an economic analysis is required to help inform policy, (iv) reliable bedside diagnostic tests for GBS in early labour are not yet available and (iv) the most important determinant of effectiveness will be compliance with a single national prevention policy.
CONCLUSIONS: As an interim measure a GBS risk-based prevention strategy is recommended. This exposes the least numbers of women and their babies to antibiotics, while virtually preventing all deaths from GBS sepsis. Continuing education of health professionals and pregnant women, auditing protocol compliance, tracking adverse events amongst pregnant women, and national surveillance of neonatal sepsis and mortality rates and antibiotic resistance are necessary for the strategy's success.

Entities:  

Mesh:

Year:  2004        PMID: 15475993

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  5 in total

Review 1.  Prevention of group B streptococcal neonatal disease revisited. The DEVANI European project.

Authors:  J Rodriguez-Granger; J C Alvargonzalez; A Berardi; R Berner; M Kunze; M Hufnagel; P Melin; A Decheva; G Orefici; C Poyart; J Telford; A Efstratiou; M Killian; P Krizova; L Baldassarri; B Spellerberg; A Puertas; M Rosa-Fraile
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09       Impact factor: 3.267

2.  Epidemiology of early-onset neonatal group B streptococcal infection: implications for screening.

Authors:  Gerald Konrad; Alan Katz
Journal:  Can Fam Physician       Date:  2007-06       Impact factor: 3.275

3.  Prevention of neonatal group B streptococcal infection: approaches of physicians in Winnipeg, Man.

Authors:  Gerald Konrad; Susan Hauch; Christy Pylypjuk
Journal:  Can Fam Physician       Date:  2007-02       Impact factor: 3.275

4.  Unnecessary workup of asymptomatic neonates in the era of group B streptococcus prophylaxis.

Authors:  Brad Buckler; Jason Bell; Ralph Sams; William Cagle; Sue Anne Bell; Carla Allen; Don Sutherland; Jatinder Bhatia
Journal:  Infect Dis Obstet Gynecol       Date:  2010-08-22

5.  The Probiotics in Pregnancy Study (PiP Study): rationale and design of a double-blind randomised controlled trial to improve maternal health during pregnancy and prevent infant eczema and allergy.

Authors:  Christine Barthow; Kristin Wickens; Thorsten Stanley; Edwin A Mitchell; Robyn Maude; Peter Abels; Gordon Purdie; Rinki Murphy; Peter Stone; Janice Kang; Fiona Hood; Judy Rowden; Phillipa Barnes; Penny Fitzharris; Jeffrey Craig; Rebecca F Slykerman; Julian Crane
Journal:  BMC Pregnancy Childbirth       Date:  2016-06-03       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.